<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02258061</url>
  </required_header>
  <id_info>
    <org_study_id>H-3-2011-034</org_study_id>
    <nct_id>NCT02258061</nct_id>
  </id_info>
  <brief_title>Optimal Cardiac Resynchronization Therapy Pacing Rate</brief_title>
  <official_title>Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-ischemic Heart Failure Patients: a Randomized Crossover Pilot Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal pacing rate during cardiac resynchronization therapy (CRT) is not known.
      Investigators investigate the impact of changing basal pacing frequencies on autonomic nerve
      function, cardiopulmonary exercise capacity and self-perceived quality of life (QoL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blinded randomized crossover pilot study testing two basal pacing rates:
      DDD-60 versus DDD-80. Each patient is paced for 2 periods of 90 days with DDD-60 and DDD-80
      in a randomly sequence.

      Blood samples NT-proBNP plasma levels are analysed at baseline and at the end of each phase
      using electrochemiluminescence-immunoassay. Patients rest for 15 minutes before the samples
      are taken.

      These result are monitored by supervisory group to ensure that increase of more than 15% than
      baseline values result in termination of study.

      Investigators conduct two distinct questionnaires (Minnesota Living with Heart Failure
      (LIfHE) questionnaire and Medical Outcome Survey Short Form (SF-36)) A symptom limiting
      bicycle (Ergoline, Baden-Württemberg, Germany) exercise test is performed to measure maximum
      work capacity and oxygen consumption at each phase.

      Recordings of resting muscle sympathetic nerve activity (MSNA) are sought in all patients at
      both rates of pacing. All patients are studied on the same set-up in the semi-recumbent
      position after 30 minutes of rest. Tungsten microelectrodes (Iowa Bioengineering) are
      inserted into the common peroneal nerve just below the knee.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>N-terminal pro-brain natriuretic peptide</measure>
    <time_frame>3 months</time_frame>
    <description>Observing the change in N-terminal pro-brain natriuretic peptide in 15 patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autonomic nerve function</measure>
    <time_frame>3 months</time_frame>
    <description>Autonomic nerve function by micro-neurography measured in bursts/min and bursts/cardiac cycle in 15 patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak oxygen consumption (pVO2)</measure>
    <time_frame>3 months</time_frame>
    <description>pVO2 measured by a symptom limiting bicycle exercise test in 15 patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-perceived quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Measured with the LIfHE and SF-36 questionnaires in 15 patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cardiac Resynchronization Therapy</condition>
  <condition>Heart Failure</condition>
  <condition>Bi-ventricular Pacing</condition>
  <condition>Sympathetic Activity</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>DDD-80 pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To investigate the impact of basal pacing rates of 80-bpm (DDD-80) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) and (iii) self-perceived quality of life (QoL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DDD-60 pacing</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>To investigate the impact of basal pacing rates of 60-bpm (DDD-60) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) self-perceived quality of life (QoL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DDD-80</intervention_name>
    <description>Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.</description>
    <arm_group_label>DDD-80 pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DDD-60</intervention_name>
    <description>Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.</description>
    <arm_group_label>DDD-60 pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis with idiopathic dilated cardiomyopathy

          -  CRT device implanted (with initial indication in accordance with European guidelines)
             at least 6 months prior to inclusion.

          -  New York Heart Association functional (NYHA) class II-IV

          -  Sinus rhythm,

          -  Hemodynamically stable

          -  Biventricular pacing &gt; 90% of the time

          -  On optimal medical treatment for heart failure with no changes in medications during
             the past 3 months.

        Exclusion Criteria:

          -  NYHA I

          -  unable to perform exercise test (e.g. chronic obstructive pulmonary disease, severe
             arthritis)

          -  cancer

          -  plasma creatinine &gt; 200 micromole per litre

          -  an admission for decompensated HF or acute coronary syndrome in the preceding 3
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam A Ghotbi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet, University hospital of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Kuniyoshi RR, Martinelli M, Negrão CE, Siqueira SF, Rondon MU, Trombetta IC, Kuniyoshi FH, Laterza MC, Nishioka SA, Costa R, Tamaki WT, Crevelari ES, Peixoto Gde L, Ramires JA, Kalil R. Effects of cardiac resynchronization therapy on muscle sympathetic nerve activity. Pacing Clin Electrophysiol. 2014 Jan;37(1):11-8. doi: 10.1111/pace.12254. Epub 2013 Aug 16.</citation>
    <PMID>23952584</PMID>
  </reference>
  <reference>
    <citation>Agostoni P, Corrà U, Cattadori G, Veglia F, Battaia E, La Gioia R, Scardovi AB, Emdin M, Metra M, Sinagra G, Limongelli G, Raimondo R, Re F, Guazzi M, Belardinelli R, Parati G, Magrì D, Fiorentini C, Cicoira M, Salvioni E, Giovannardi M, Mezzani A, Scrutinio D, Di Lenarda A, Mantegazza V, Ricci R, Apostolo A, Iorio A, Paolillo S, Palermo P, Contini M, Vassanelli C, Passino C, Piepoli MF; MECKI Score Research Group. Prognostic value of indeterminable anaerobic threshold in heart failure. Circ Heart Fail. 2013 Sep 1;6(5):977-87. doi: 10.1161/CIRCHEARTFAILURE.113.000471. Epub 2013 Jul 23.</citation>
    <PMID>23881847</PMID>
  </reference>
  <reference>
    <citation>Stockburger M, de Teresa E, Lamas G, Desaga M, Koenig C, Habedank D, Cobo E, Navarro X, Wiegand U. Exercise capacity and N-terminal pro-brain natriuretic peptide levels with biventricular vs. right ventricular pacing for atrioventricular block: results from the PREVENT-HF German Substudy. Europace. 2014 Jan;16(1):63-70. doi: 10.1093/europace/eut217. Epub 2013 Jul 16.</citation>
    <PMID>23861381</PMID>
  </reference>
  <reference>
    <citation>Brenyo A, Barsheshet A, Rao M, Huang DT, Zareba W, McNitt S, Hall WJ, Peterson DR, Solomon SD, Moss AJ, Goldenberg I. Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure. Circ Heart Fail. 2013 Sep 1;6(5):998-1004. doi: 10.1161/CIRCHEARTFAILURE.112.000174. Epub 2013 Jun 25.</citation>
    <PMID>23801020</PMID>
  </reference>
  <reference>
    <citation>Shukla A, Curtis AB, Mehra MR, Albert NM, Gheorghiade M, Heywood JT, Liu Y, O'Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Factors associated with improvement in utilization of cardiac resynchronization therapy in eligible heart failure patients: findings from IMPROVE HF. Pacing Clin Electrophysiol. 2013 Apr;36(4):433-43. doi: 10.1111/pace.12090. Epub 2013 Feb 4.</citation>
    <PMID>23380000</PMID>
  </reference>
  <reference>
    <citation>Martin DO, Day JD, Lai PY, Murphy AL, Nayak HM, Villareal RP, Weiner S, Kraus SM, Stolen KQ, Gold MR. Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial. J Cardiovasc Electrophysiol. 2012 Dec;23(12):1317-25. doi: 10.1111/j.1540-8167.2012.02402.x. Epub 2012 Jul 25.</citation>
    <PMID>22830441</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2014</study_first_posted>
  <last_update_submitted>October 6, 2014</last_update_submitted>
  <last_update_submitted_qc>October 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Dr. Adam Ali Ghotbi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

